Stock Rating Runner: Aclaris Therapeutics (NASDAQ:ACRS) Gets Another Recommendation On Wall Street. This time with $54.00 PT

November 30, 2016 - By Darrin Black

Stock Rating Runner: Aclaris Therapeutics (NASDAQ:ACRS) Gets Another Recommendation On Wall Street. This time with $54.00 PT

Why Leerink Swann Gives Aclaris Therapeutics (NASDAQ:ACRS) $54.00 Price Target

Leerink Swann initiated its coverage on Aclaris Therapeutics (NASDAQ:ACRS), today Tuesday morning. Investment firm finds the stock of ACRS attractive and has TP of $54.00 with Outperform rating.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 5 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $54 is the highest target while $20 is the lowest. The $37.25 average target is 23.59% above today’s ($30.14) stock price. Aclaris Therapeutics has been the topic of 9 analyst reports since November 2, 2015 according to StockzIntelligence Inc. Jefferies maintained Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Friday, August 12. Jefferies has “Buy” rating and $23 price target. The stock has “Outperform” rating given by William Blair on Monday, November 2. The firm has “Market Perform” rating given on Friday, September 30 by JMP Securities. The rating was initiated by Guggenheim with “Buy” on Friday, June 10. The rating was maintained by Jefferies with “Buy” on Monday, September 19. The rating was initiated by Jefferies on Monday, November 2 with “Buy”. As per Monday, November 2, the company rating was initiated by Citigroup. The firm earned “Outperform” rating on Tuesday, November 29 by Leerink Swann.

The stock increased 7.49% or $2.1 on November 29, hitting $30.14. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 47.17% since April 27, 2016 and is uptrending. It has outperformed by 41.94% the S&P500.

Analysts await Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings on March, 22. They expect $-0.67 EPS, down 139.29% or $0.39 from last year’s $-0.28 per share. After $-0.50 actual EPS reported by Aclaris Therapeutics Inc for the previous quarter, Wall Street now forecasts 34.00% negative EPS growth.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $793.13 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis , a non-malignant skin tumor.

According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

More news for Aclaris Therapeutics Inc (NASDAQ:ACRS) were recently published by: Fool.com, which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Investorplace.com‘s article titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>